XML 29 R14.htm IDEA: XBRL DOCUMENT
v3.24.1

Note 8 - Other Intangible Assets | 12 Months Ended
--- | ---
Dec. 31, 2023
Notes to Financial Statements |
Intangible Assets Disclosure [Text Block] | NOTE 8. OTHER INTANGIBLE ASSETS As of December 31, 2023 and 2022, other intangible assets consisted of the following (in thousands):
|  | Balance at December 31, 2023 |
|  |  |  |  |  | Accumulated |  |  | Impairments |  |  |  |  |
|  | Gross |  |  | Amortization |  |  | to Date |  |  | Net |
Indefinite-lived intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Trade names |  | $ | 2,080 |  |  | $ | — |  |  | $ | (2,080 | ) |  | $ | — |
Amortizable intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Customer relationships |  |  | 290 |  |  |  | (60 | ) |  |  | (230 | ) |  |  | — |
Trade secrets / product formulations |  |  | 2,890 |  |  |  | (515 | ) |  |  | (2,375 | ) |  |  | — |
Total other intangible assets |  | $ | 5,260 |  |  | $ | (575 | ) |  | $ | (4,685 | ) |  | $ | — |
|  | Balance at December 31, 2022 |
|  |  |  |  |  | Accumulated |  |  | Impairments |  |  |  |  |  |  |  |
|  | Gross |  |  | Amortization |  |  | to Date |  |  | Net |
Indefinite-lived intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Trade names |  | $ | 2,080 |  |  | $ | — |  |  | $ | (970 | ) |  | $ | 1,110 |
Amortizable intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Customer relationships |  |  | 290 |  |  |  | (48 | ) |  |  | (172 | ) |  |  | 70 |
Trade secrets / product formulations |  |  | 2,890 |  |  |  | (375 | ) |  |  | (1,415 | ) |  |  | 1,100 |
Total other intangible assets |  | $ | 5,260 |  |  | $ | (423 | ) |  | $ | (2,557 | ) |  | $ | 2,280 |
In each of the fourth quarters of 2023 and 2022, the Company determined that certain of its indefinite-lived and long-lived amortizable intangible assets related to its DERMAdoctor business were impaired, including fully impaired as of December 31, 2023. As such, the Company recorded an intangible asset impairment charge of $2.1 million and $2.6 million in the years ended December 31, 2023 and 2022, respectively, which is reflected in the goodwill, intangible and other asset impairment caption in the Company’s consolidated statements of operations. The impairment information is discussed in Note 2, “Summary of Significant Accounting Policies”. Subsequent to December 31, 2023, on March 25, 2024, we closed the DERMAdoctor Divestiture. See additional information in Note 21, “Subsequent Events”. Amortization expense was $152 thousand and $363 thousand for the years ended December 31, 2023 and 2022, respectively.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for all or part of the information related to intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//350-30/tableOfContent + Details
Name: | us-gaap_IntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration